Along the PP2A pathway, the cancerous inhibitor of protein phosphatase 2A (CIP2A) protein has been found to be a relevant player in CML BP progression, as has previously been demonstrated in other malignancies. The gene discussed is CIP2A; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.